Heart Failure and Cardiac Device Therapy: A Review of Current NICE and ESC Guidelines

Naraen A, Duvva D, Rao A

Supplementary Material

Supplementary Table 1: Indications for Cardiac Device Therapy Included in ESC Guidance vs NICE Guidance

	ESC	NICE
Bradypacing		
Sinus Node Dysfunction		
Symptomatic	✓	✓
Tachy-Brady syndrome + Pharmacological management	✓	
Patients with syncope + documented asymptomatic 6 sec pause	✓	
Symptomatic patients likely secondary to bradyarrhythmia without conclusive evidence	√	
Transient sinus node dysfunction due to correctable causes	√	
AV block		
Permanent or paroxysmal type II 2 nd or 3 rd degree AV block irrespective of symptoms	✓	✓
AF + 3 rd degree or high degree AV block	✓	✓
Symptomatic type I 2 nd degree AV block or located at intra or infra His levels on EPS	√	
Symptoms similar to that of pacemaker syndrome attributable to 1 st degree AV block with a PR interval of >0.3sec	√	
Transient AV block due to correctable causes	✓	
Bundle branch block		
Alternating bundle branch block irrespective of symptoms	✓	
Bifasicular block + unexplained syncope + HV time of >70ms, 2 nd or 3 rd degree	✓	
intra- or infra-Hisian block during incremental atrial pacing, or an abnormal		
response to pharmacological challenge		
Unexplained syncope and bifascicular block without EP study in elderly, frail patients, high-risk and/ or recurrent syncope	✓	
Asymptomatic bifasicular or bundle branch block	✓	
Reflex Syncope		
Reduction of recurrent syncope in patients aged >40 years, with severe, unpredictable, recurrent syncope who have: spontaneous documented symptomatic asystolic pause(s) >3 s or asymptomatic pause(s) >6 s due to sinus arrest or AVB; or cardioinhibitory carotid sinus syndrome; or asystolic syncope during tilt testing	✓	
Reduction of syncope recurrences in patients with the clinical features of	√	
adenosine-sensitive syncope		
Undocumented (suspected) syncope and recurrent falls		
Unexplained falls without documented indications	✓	
Unexplained syncope without evidence of documented indications	✓	
CRT		
Patients in Sinus rhythm		
LBBB		

Symptomatic with EF ≤35% QRS ≥ 150ms despite OMT	✓		√ †
Symptomatic with EF ≤35% QRS = 130-149ms despite OMT	✓		√ †
Non-LBBB			
Symptomatic with EF ≤35% QRS ≥ 150ms despite OMT	√		√ †
Symptomatic with EF ≤35% QRS = 130-149ms despite OMT	✓		√ †
Patients in AF			
Permanent AF with ≤ LVEF 35% + NYHA III/IV + ≥ QRS 130ms	✓		√ †
AF + AV Node ablation			
Heart failure with Reduced Ejection Fraction (HFrEF)	✓		
Heart failure with mildly Reduced Ejection Fraction	✓		
Guidance on right ventricular pacing over CRT in Heart Failure with	✓		
preserved Ejection Fraction			
Pre-existing pacemaker or ICD			
Upgrade to CRT if subsequent development of symptomatic HF (LVEF	✓		
<35%) despite best medical management whilst having a significant RV			
pacing			
Heart Failure and AV block			
Ejection Fraction <40% + high degree AV block (including AF)	✓		
Implantable Cardioverter Defibrillator + CRT			
Stand-alone indication for ICD who require a CRT = CRT-d	✓		
ICD			
ICD implantation (General principles)			
In patients with an expected good quality survival >1 year		✓	
Primary Prevention ICD			
Symptomatic VT		✓	✓
High risk channelopathies		✓	✓
High risk cardiomyopathies		✓	✓
High risk congenital heart disease		✓	✓
Post-myocardial infarction and persistent EF ≤40% 6-12 weeks after MI		✓	
Asymptomatic + OMT + coronary artery disease + LVEF ≤30% + narrow C	QRS	✓	✓
Symptomatic + OMT + coronary artery disease + LVEF ≤ 35%			
Secondary prevention of sudden cardiac death (SCD)			
Documented VF		✓	✓
SCD secondary to ventricular arrythmias without ongoing ischaemia with	ı	✓	
documented VF or haemodynamically not-tolerated VT occurring later t	nan		
48 h after MI			
Secondary prevention in VF/ haemodynamic unstable VT in those with		✓	
channelopathies, cardiomyopathies, congenital heart disease			
Survived cardiac arrest due to VT or VF		✓	✓
Adding CRT to ICD			
When an ICD is indicated, evaluate whether the patient could benefit from	om	✓	
CRT-d			

Subcutaneous implantable cardioverter-defibrillator		
An alternative to transvenous defibrillator with an indication for ICD when	✓	√ ∎
pacing therapy for bradycardia, CRT or anti-tachycardia pacing is not needed		
Wearable cardioverter defibrillator		
Indication for secondary prevention ICD but are temporarily not candidates	✓	
for ICD implantation		
Consider in early phase of MI in selected patients	✓	
Optimisation of device programming	✓	
ICD implantation in left ventricular assist device (LVAD) recipients		
Consider ICD implantation in LVAD recipients with symptomatic sustained	✓	
ventricular arrythmias		
End-of-life issues in ICD carriers		
Informed discussion with patient and family about deactivation options and	✓	
shared decision making is indicated prior to implantation and in case of		
significant health status deterioration		
Temporary pacing		
Indications for transcutaneous pacing	✓	
Indications for transvenous pacing	✓	
Other pacing modalities		
His bundle pacing (HBP)		
In unsuccessful coronary sinus lead implantation, consider HBP along with	✓	
other options like surgical epicardial lead		
Implantation of right ventricular lead used as back up for pacing or sensing	✓	
HBP with ventricular backup lead in pace and ablate strategy for rapidly	✓	
conducted supraventricular arrhythmia particularly when intrinsic QRS is		
narrow		
Research context only		✓
Left bundle branch area pacing		
Potential role: blocks that are too distal to be treated with HBP + facilitates	✓	
AV node ablation,		
Leadless pacing		
Absence of upper extremity venous access or high risk of device pocket	✓	√ ††
infection		
As an alternative to standard single lead ventricular pacing	✓	

Supplementary Table 2: Heart Failure Management Included in ESC Guidance vs NICE Guidance

	ESC	NICE
Acute heart failure		
Initial management		
Oxygen to maintain saturations or to correct hypoxaemia	✓	
NIV to reduce the rate of mechanical intubation	✓	✓
Intubation for progressive respiratory failure persisting despite oxygen	✓	✓
administration or NIV		
Intravenous loop diuretics	✓	✓
Combination of loop + thiazide for resistant oedema	✓	
Consider vasodilators to improve symptoms and reduce congestion	✓	✓
Consider inotropes or vasopressors if reversible cardiogenic shock		✓
Other drugs		
VTE prophylaxis unless anti-coagulated	✓	
Routine use of opiated is not recommended unless severe pain or	✓	
anxiety		
Short-term mechanical support		
Considered as a bridge to bridge/recovery/decision	✓	
IABP can be considered in cardiogenic shock or long term mechanical	✓	
circulatory support or transplantation		
Arrhythmias	✓	
Revascularisation in HFrEF	✓	
Valvular heart disease and Heart Failure	✓	✓
Cancer + Heart Failure	✓	
Chronic Heart Failure		
Heart Failure with Reduced Ejection Fraction		
Initial management		_
ACE inhibitors (ACEi)	✓	✓
ARB is ACE inhibitor not tolerated	✓	✓
Betablockers (BB)	✓	✓
Mineralocorticoid receptor antagonist (MRA)	✓	✓
SGLT2 – Dapagliflozin/Empagliflozin	✓	
Sacubitril/Valsartan is recommended as a replacement for an ACE-I	✓	✓
inhibitors		
Other drugs	_	1
Loop diuretics	✓	✓
Ivabradine if resting heart rate \geq 70bpm despite betablockers or are	✓	√ ∗
unable to tolerate a betablocker		
Vericiguat if worsening heart failure despite, ACEi, BB, MRA	√	
Hydralazine	✓	√ **

- self-identified black patients + dilated left ventricle + OMT with ACEi, BB and MRA		
- Cannot tolerate one of ACEi, BB, MRA		
Isosorbide dinitrate	✓	√ **
 self-identified black patients + dilated left ventricle + OMT with 		
ACEi, BB and MRA		
- Cannot tolerate one of ACEi, BB, MRA		
Digoxin if symptomatic despite OMT with ACEi, BB, MRA	✓	✓
Multidisciplinary management of chronic HF	✓	✓
Exercise rehabilitation	✓	✓
Palliative care	✓	✓
Heart transplantation guidance	✓	
Heart Failure with Preserved Ejection Fraction		
Diuretics	✓	✓
Management of hypertension	✓	
Statins if risk of cardiovascular disease	✓	
SGLT2 inhibitors if diabetic + risk of cardiovascular disease	✓	

ACEi = ACE Inhibitors; BB = betablockers; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; IABP = intra-aortic balloon pump; MDT = multidisciplinary team; MRA = mineralocorticoid receptor antagonist; NIV = non-invasive ventilation; OMT = optimised medical therapy; VTE = venous thrombo-embolism.

- † = Not specified if in sinus rhythm
- = Supports use but does not include indications
- $\dagger\dagger$ = If MDT concludes conventional pacemaker is contraindicated with special arrangements for clinical governance, audit, consent and research
- * = If heart rate >75bpm
- ** = Combination therapy only, no specific direction